Sift Biosciences

About Sift Biosciences

Sift Bio is a biotech company focused on building a proprietary peptide immunotherapy platform using AI, metagenomics, and high-throughput T-cell screening. Their mission is to discover peptides that amplify immune responses, providing targeted, effective, and safe treatments for cancer and autoimmune diseases, with the ultimate goal of bringing durable disease control to every patient.

Products & Services

Peptide Immunotherapy Platform:A platform combining AI-driven discovery, metagenomics, and T-cell screening to develop peptides that enhance immune responses for treating cancer and autoimmune diseases.

T-cell Modulators:A novel class of modulators derived from bacteria and viruses to activate memory T cells for targeting cancer and immune-dysregulated diseases.

Specialties

AI-driven discovery Metagenomics High-throughput T-cell screening Immunotherapy Peptide-based therapies Cancer treatment Autoimmune disease treatment

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Pre-Seed T: - FT: Pre-Seed	A: 3700000 MR: - FA: 3.7M FAN: 3700000	D: 2026-02-18 FD: 2026-02-18	6 investors

Pre-Seed Latest

2026-02-18

$3.7M

6 investors (Pro only)

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

Y

Yue Clare Lou

Founder & CEO

LinkedIn (Pro only)

M

Maddie Williams

Founder & CTO

LinkedIn (Pro only)

A

Andrew Conroy

Principal Scientist

LinkedIn (Pro only)

M

Marcela Briones

Senior Scientist

M

MaryClare Rollins

Senior Scientist

J

Jill Banfield

View 6 more team members with Pro

Unlock Full Team Directory

Recent News